



Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/006,205
Filing Date	December 10, 2001
First Named Inventor	Tauer, et al.
Group Art Unit	1632
Examiner Name	Not yet assigned
Attorney Docket Number	20695C-002000US

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900
class/subclass

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BOL	AA	4,783,407		Provost et al.	11/08/88	
BOL	AB	5,268,292		Robertson et al.	12/07/93	
BOL	AC	5,858,658		Haemmerle et al.	01/12/99	
BOL	AD	6,100,061		Reiter et al.	08/08/00	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
BOL	AE	PCT	WO 96/15231			05/23/96		
BOL	AF	PCT	WO 00/23574			04/27/00		
BOL	AG	Europe	0 339 667 B1			04/28/89		
BOL	AH	Europe	0 339 668 A2			04/28/89		
BOL	AI	Europe	0 583 142 A2			08/06/93		

Examiner Signature

Brogan

Date Considered

08/14/2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1338503 v1



Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/006,205
Filing Date	December 10, 2001
First Named Inventor	Tauer, et al.
Group Art Unit	1632
Examiner Name	Not yet assigned
Attorney Docket Number	20695C-002000US

RECEIVED

NOV 13 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BLC	AJ	Andre, et al., <i>Inactivated Candidate Vaccines for Hepatitis A</i> , <u>Prog. Med. Virol.</u> , Vol. 37, Pg. 72-95 (1990).	
BLC	AK	Armstrong, et al., <i>Development of the Formalin-Inactivated hepatitis A Vaccine, VAQTATM from the Live Attenuated Virus Strain CR326F</i> , <u>J. of Hepatology</u> , Vol. 18, Pg. 20-26 (1993).	
BLC	AL	Bader, <i>Hepatitis A Vaccine</i> , <u>Amer. Journal of Gastroenterology</u> , Vol. 91:2, Pg. 217-222 (1996).	
BLC	AM	Binn, et al., <i>Primary Isolation and Serial Passage of Hepatitis A Virus Strains in Primate Cell Cultures</i> , <u>Journal of Clinical Microbiology</u> , Vol. 20:1, Pg. 28-33 (1984).	
BLC	AN	Binn, et al., <i>Preparation of a Prototype Inactivated Hepatitis A Virus Vaccine from Infected Cell Cultures</i> , <u>Journal of Infectious Diseases</u> , Vol. 153:4, Pg. 749-756 (1986).	
BLC	AO	Bishop, et al., <i>Rapid and Efficient Purification of Hepatitis A Virus from Cell Culture</i> , <u>Journal of Virological Methods</u> , Vol. 47, Pg. 203-216 (1994).	
BLC	AP	Bishop, et al., <i>Hepatitis A Virus Subviral Particles: Purification, Accumulation, and Relative Infectivity of Virions, Provirions and Procapsids</i> , <u>Arch. Virol.</u> , Vol. 142, Pg. 2147-2160 (1997).	
BLC	AQ	Cinatl Jr., et al., <i>Protein-Free Culture of Vero Cells: A Substrate for Replication of Human Pathogenic Viruses</i> , <u>Cell Biology International</u> , Vol. 17:9, Pg. 885-895 (1993).	
BLC	AR	Cohen, et al., <i>Hepatitis A Virus cDNA and Its RNA Transcripts Are Infectious in Cell Culture</i> , <u>Journal of Virology</u> , Vol. 61:10, Pg. 3035-3040 (1987).	
BLC	AS	Dubois, et al., <i>Large-Scale Purification of Inactivated Hepatitis A Virus by Centrifugation in Non-Ionic Gradients</i> , <u>Journal of Virological Methods</u> , Vol. 32, Pg. 327-334 (1991).	
BLC	AT	Flehmgig, et al., <i>Immunogenicity of a Hepatitis A Virus Vaccine</i> , <u>Journal of Medical Virology</u> , Vol. 22, Pg. 7-16 (1987).	
BLC	AU	Hagen, et al., <i>Use of a Nuclease Enzyme in the Purification of VAQTA®, a Hepatitis A Vaccine</i> , <u>Biotechnology Appl. Biochem.</u> , Vol. 23, Pg. 209-215 (1996).	
BLC	AV	Hennessey Jr., et al., <i>Evaluation of the Purity of a Purified, Inactivated Hepatitis A Vaccine (VAQTATM)</i> , <u>Vaccine</u> , Vol. 17, Pg. 2830-2835 (1999).	

Examiner
Signature

Basquini

Date
Considered

08/25/2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. - SF 1338503 v1



Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/006,205
Filing Date	December 10, 2001
First Named Inventor	Tauer, et al.
Group Art Unit	1632
Examiner Name	Not yet assigned
Attorney Docket Number	20695C-002000US

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BLC	AW	Kessler, et al., <i>Suitability of MDCK Cells Grown in a Serum-Free Medium for Influenza Virus Production</i> , <i>Dev. Biol. Stand.</i> , Vol. 98, Pg. 13-21 (1999).	
BCL	AX	Kistner, et al., <i>Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine</i> , <i>Vaccine</i> , Vol. 16: 9/10, Pg. 960-968 (1998).	
BLC	AY	Lemon, et al., <i>Antigenic Structure of Hepatitis A Virus</i> , <i>Molecular Aspects of Picornavirus Infection and Detection</i> , Pg. 193-208 (1989).	
BLC	AZ	Locamini, et al., <i>Restricted Replication of Human Hepatitis A Virus in Cell Culture: Intracellular Biochemical Studies</i> , <i>Journal of Virology</i> , Vol. 37:1, Pg. 216-225 (1981).	
BLC	BA	Merten, et al., <i>Evaluation of the New Serum-Free Medium (MDSS2) for the Production of Different Biologicals: Use of Various Cell Lines</i> , <i>Cytotechnology</i> , Vol. 14, Pg. 47-59 (1994).	
BLC	BB	Nasser et al., <i>Production of Cytopathology in FRhK-4 Cells by BS-C-1-Passaged Hepatitis A Virus</i> , <i>Applied and Environmental Microbiology</i> , Vol. 53:12, Pg. 2967-2971 (1987).	
BLC	BC	Yokosawa, et al., <i>Affinity Chromatography of Trypsin and Related Enzymes</i> , <i>Journal Biochem.</i> , Vol. 79, Pg. 757-763 (1976).	

Examiner
Signature

Bargumh

Date
Considered

8/28/2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1338503 v1